- Report
- May 2024
- 192 Pages
Global
From €3237EUR$3,374USD£2,788GBP
€3597EUR$3,749USD£3,098GBP
- Report
- March 2024
- 198 Pages
Global
From €3237EUR$3,374USD£2,788GBP
€3597EUR$3,749USD£3,098GBP
- Report
- May 2024
- 196 Pages
Global
From €4749EUR$4,950USD£4,091GBP
- Drug Pipelines
- April 2024
- 180 Pages
Global
From €1919EUR$2,000USD£1,653GBP
- Clinical Trials
- April 2024
- 50 Pages
Global
From €1439EUR$1,500USD£1,240GBP
- Report
- March 2024
- 150 Pages
Global
From €5709EUR$5,950USD£4,917GBP
- Report
- January 2024
- 200 Pages
Global
From €4797EUR$5,000USD£4,132GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1919EUR$2,000USD£1,653GBP
- Report
- November 2023
- 171 Pages
Global
From €2399EUR$2,500USD£2,066GBP
- Report
- December 2023
- 182 Pages
Global
€4793EUR$4,995USD£4,128GBP
- Report
- July 2022
- 100 Pages
Global
From €2639EUR$2,750USD£2,273GBP
- Report
- January 2022
- 200 Pages
Global
From €7196EUR$7,500USD£6,198GBP
- Report
- January 2022
- 200 Pages
Global
From €7196EUR$7,500USD£6,198GBP
- Report
- January 2022
- 200 Pages
Global
From €7196EUR$7,500USD£6,198GBP
- Report
- January 2022
- 60 Pages
Global
From €3790EUR$3,950USD£3,264GBP
- Report
- January 2022
- 200 Pages
Global
From €7196EUR$7,500USD£6,198GBP
- Report
- January 2022
- 60 Pages
Global
From €3790EUR$3,950USD£3,264GBP
- Report
- July 2022
- 131 Pages
Global
From €4318EUR$4,500USD£3,719GBP
- Report
- January 2022
- 120 Pages
Global
From €2399EUR$2,500USD£2,066GBP
- Report
- August 2022
United States
From €1861EUR$1,940USD£1,603GBP
Diabetic Neuropathy Drug is a type of Central Nervous System (CNS) drug used to treat nerve damage caused by diabetes. It works by blocking the transmission of pain signals from the nerves to the brain. Commonly used drugs include anticonvulsants, antidepressants, and opioids. These drugs can help reduce pain, improve sleep, and improve quality of life. Side effects may include drowsiness, dizziness, and nausea.
The Diabetic Neuropathy Drug market is a rapidly growing segment of the CNS drug market. It is driven by the increasing prevalence of diabetes, as well as the need for effective treatments for diabetic neuropathy. The market is expected to continue to grow in the coming years, as new treatments are developed and approved.
Some companies in the Diabetic Neuropathy Drug market include Pfizer, Novartis, Merck, and GlaxoSmithKline. Show Less Read more